Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

NCT02232646 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.

NCT NCT02232646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02232646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Lead sponsor
Sumitomo Pharma America, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2017
Completion date
August 1, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma, urologic malignancies, urothelial carcinoma